AstraZeneca Launches Two Nutrition Websites

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Daniel C. McFarland, DO, and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.

How John G. Phillips, MD, MPH, and Tennessee Oncology are aiming to expand radiation oncology access in smaller communities across Tennessee.